Joint ICON and Pfizer team win award for excellence in study start-up and patient recruitment in cardiovascular outcome studies
The award honoured the achievements of the team that has made the most difference to a pharmaceutical or biotechnology company's research program, and has made great strides on its core project through exemplary team-working.
ICON and Pfizer won the award for their achievements in 2015 on two ongoing parallel cardiovascular outcome studies, which will involve approximately 26,000 patients at 3,000 sites in 35 countries. Through close collaboration and by adopting a single team approach, ICON and Pfizer designed a framework that re-engineered the site start-up process and enabled them to meet or exceed the studies' site activation and patient enrolment targets for 2015.
Pfizer has created SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events), an extensive research program to study bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The SPIRE Phase 3 global clinical development program consists of six lipid-lowering studies (SPIRE-SI, SPIRE-AI, SPIRE-HR, SPIRE-FH, SPIRE-LL and SPIRE-LDL) as well as two cardiovascular outcome studies (SPIRE-1 and SPIRE-2).
The two cardiovascular outcome studies are investigating the ability of bococizumab to reduce the risk of cardiovascular events in a broad range of high-risk primary and secondary prevention patients, including those with diabetes, chronic kidney disease, peripheral vascular disease or familial hypercholesterolemia, in addition to those with previous cardiovascular events such as heart attack, stroke, or cardiovascular revascularization procedures.
Commenting on the award, ICON's Chief Executive,
Commenting on the award, Pfizer's Vice President for Clinical
Bococizumab is an investigational compound and has not received regulatory approval in any country.
The inaugural CARE Awards celebrate the outstanding clinical research
achievements from 2015. The awards showcase excellence in clinical trial
design, technological advancements within the industry, outstanding
research results, as well as achievements of individuals, departments,
teams, or organizations. Award winners have contributed to the
advancement of therapies for unmet medical needs, undertaken
ground-breaking collaborations, and contributed to positive clinical
outcomes while demonstrating best practices and innovation. More detail
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in
ICON Media Contact
+44 (0) 207 067 0272
News Provided by Acquire Media